Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA Oncology

• Publication date

  2017-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaoncol.2017.1968PMID 28772291PMCID PMC5824277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?

  2017cited by this paper
• Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls

  2017cited by this paper
• Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.

  2016cited by this paper
• Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort

  2016cited by this paper
• Easing the Burden: Describing the Role of Social, Emotional and Spiritual Support in Research Families with Li-Fraumeni Syndrome

  2016cited by this paper
• metaSEM: an R package for meta-analysis using structural equation modeling

  2015cited by this paper
• Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.

  2015cited by this paper
• Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.

  2014cited by this paper
• Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.

  2013cited by this paper
• What do we know about who does and does not attend general health checks? Findings from a narrative scoping review

  2012cited by this paper
• Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.

  2012cited by this paper
• Eligibility for Magnetic Resonance Imaging Screening in the United Kingdom: Effect of Strict Selection Criteria and Anonymous DNA Testing on Breast Cancer Incidence in the MARIBS Study

  2009cited by this paper
• 2009 version of the Chompret criteria for Li Fraumeni syndrome.

  2009cited by this paper
• Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families

  2008cited by this paper
• Factors Affecting Sensitivity and Specificity of Screening Mammography and MRI in Women with an Inherited Risk for Breast Cancer

  2006cited by this paper
• Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.

  2006cited by this paper
• Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.

  2005cited by this paper
• Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

  2005cited by this paper
• Germline TP53 mutations and Li‐Fraumeni syndrome

  2003cited by this paper
• The IARC TP53 database: New online mutation analysis and recommendations to users

  2002cited by this paper
• Sensitivity and predictive value of criteria for p53germline mutation screening

  2001cited by this paper
• P53 germline mutations in childhood cancers and cancer risk for carrier individuals

  2000cited by this paper
• Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions

  1998cited by this paper
• Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

  1990cited by this paper
• Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome

  1990cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

  1969cited by this paper

• SIGNIFIED: whole-body MRI screening in Li-Fraumeni syndrome in the UK.

  2026cites this paper
• Parent and Patient Proxies' Preferences on Whole-Body MRI Techniques for Cancer Predisposition Syndromes' Surveillance.

  2025cites this paper
• Treatment Experience of Pelvic Osteosarcoma Arising in Li-Fraumeni Syndrome

  2025influential citation
• Prospective Study of Annual Whole-Body Magnetic Resonance Imaging as Part of a Multimodality Screening Program for Individuals With Li-Fraumeni Syndrome.

  2025cites this paper
• A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome

  2025cites this paper
• Optimizing whole-body MRI for early cancer detection in Li-Fraumeni syndrome: a prospective bicentric study.

  2025influential citation
• [Unexpected liver tumors in a patient with Li-Fraumeni syndrome].

  2025cites this paper
• Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.

  2025cites this paper
• Shared decision-making in radiology: leadership levers for patient-centred imaging

  2025cites this paper
• U-Swing: An Adaptive U-Net and Swin Fusion for WB-MRI Whole Spine Bone Marrow Segmentation.

  2025cites this paper
• A patient with newly diagnosed breast cancer found to have mosaic TP53 likely pathogenic variant

  2025cites this paper
• Peripheral blood DNA methylation predicts the early onset of primary tumor in TP53 mutation carriers

  2025cites this paper
• Evaluation of whole-body MRI for cancer early detection in Li-Fraumeni syndrome

  2025cites this paper
• The argument for screening programs in previvors with Li-Fraumeni syndrome

  2025cites this paper
• The TP53 tumor suppressor gene: From molecular biology to clinical investigations

  2025cites this paper
• Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories

  2025cites this paper
• Modeled Benefit of Individual Cancer Signal Origin Prediction for Multi-Cancer Early Detection

  2025cites this paper
• Anaplastic Lymphoma Kinase Inhibition Therapy for Hereditary Neuroblastoma

  2025cites this paper
• Genetic predisposition in sarcomas: clinical implications and management

  2025cites this paper
• Utility of Whole-Body Magnetic Resonance Imaging Surveillance in Children and Adults With Cancer Predisposition Syndromes: A Retrospective Study

  2025cites this paper
• Incidental findings in surveillence of paediatric Li Fraumeni patients – A single centre experience

  2025influential citation
• Whole-Body MRI in Children: Concepts and Controversies-AJR Expert Panel Narrative Review.

  2025cites this paper
• Bone sarcomas and cancer predisposition syndromes.

  2025cites this paper
• Characterization of sarcoma topography in Li-Fraumeni syndrome

  2024cites this paper
• The Importance of Genetic Screening on the Syndromes of Colorectal Cancer and Gastric Cancer: A 2024 Update

  2024cites this paper
• Adrenocortical tumors and hereditary syndromes

  2024cites this paper
• Li–Fraumeni‐associated osteosarcomas: The French experience

  2024cites this paper
• Utility of genomic testing in children, adolescents, and young adults with cancer.

  2024cites this paper
• Patterns of Growth of Tumors in Li-Fraumeni Syndrome by Imaging: A Case Series

  2024cites this paper
• Characterizing Lung Cancer in Li-Fraumeni Syndrome.

  2024cites this paper
• Baseline surveillance in Li Fraumeni syndrome using whole-body MRI: a systematic review and updated meta-analysis

  2024cites this paper
• Feasibility of whole‐body MRI for cancer screening in children and young people with ataxia telangiectasia: A mixed methods cross‐sectional study

  2024cites this paper
• Multiparametric Whole-Body MRI: A Game Changer in Metastatic Prostate Cancer

  2024cites this paper
• Present and future of whole-body MRI in metastatic disease and myeloma: how and why you will do it

  2024cites this paper
• Quand le cancer commence tôt

  2024cites this paper
• New Paradigms in the Clinical Management of Li-Fraumeni Syndrome.

  2024cites this paper
• Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum

  2024cites this paper
• Whole-Body MRI Screening for Carriers of Germline TP53 Mutations—A Systematic Review and Meta-Analysis

  2024cites this paper
• Relations of body dissatisfaction with self-injurious thoughts and behaviours in clinical and non-clinical samples: a meta-analysis of studies published between 1995 and 2022

  2024cites this paper
• Development of cancer surveillance guidelines in ataxia telangiectasia: A Delphi‐based consensus survey of international experts

  2023cites this paper
• SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)

  2023cites this paper
• Modeled residual current cancer risk after clinical investigation of a positive multicancer early detection test result

  2023cites this paper
• Whole‐body MRI for cancer surveillance in ataxia–telangiectasia: A qualitative study of the perspectives of people affected by A‐T and their families

  2023cites this paper
• Imaging Recommendations for Diagnosis, Staging, and Management of Hereditary Malignancies

  2023cites this paper
• Germline TP53 pathogenic variants and breast cancer: A narrative review.

  2023cites this paper
• Understanding cancer predisposition in Singapore: what's next

  2023cites this paper
• Surveillance imaging and early surgical intervention for improved CNS tumor outcomes in children with Li-Fraumeni syndrome: Children's National Hospital experience and literature review.

  2023cites this paper
• Whole‐body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study

  2023cites this paper
• NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.

  2023cites this paper
• Rates of intervention and cancer detection on initial versus subsequent whole body MRI screening in Li-Fraumeni Syndrome.

  2023cites this paper
• Rate of Pathogenic Germline Variants in Patients With Lung Cancer

  2023cites this paper
• Benign single-nucleotide polymorphisms in the coding region of TP53: finding the needles in a haystack of pathogenic variants.

  2022cites this paper
• Biology-Guided Precision Medicine in Rare Cancers: Lessons from Sarcomas and Neuroendocrine Tumours.

  2022cites this paper
• Cancer surveillance for patients with Li-Fraumeni Syndrome in Brazil: A cost-effectiveness analysis

  2022cites this paper
• Invited editorial: Q and A on hereditary lung cancer.

  2022cites this paper
• Diagnostic accuracy of imaging approaches for early tumor detection in children with Li-Fraumeni syndrome

  2022cites this paper
• Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome

  2022cites this paper
• Volume-based Performance not Guaranteed by Promising Patch-based Results in Medical Imaging

  2022cites this paper
• Cancer incidence and surveillance strategies in individuals with RASopathies

  2022cites this paper
• Initial outcomes and insights from a novel high‐risk prostate cancer screening clinic

  2022cites this paper
• Whole-Body MRI Surveillance—Baseline Findings in the Swedish Multicentre Hereditary TP53-Related Cancer Syndrome Study (SWEP53)

  2022cites this paper
• Clinical Applications and Controversies of Whole-Body MRI: AJR Expert Panel Narrative Review.

  2022cites this paper
• Li-Fraumeni-Syndrom

  2022cites this paper
• Ganzkörper-MRT bei Tumorprädispositionssyndromen

  2022cites this paper
• Free‐breathing accelerated whole‐body MRI using an automated workflow: Comparison with conventional breath‐hold sequences

  2022influential citation
• Improving protocols for whole-body magnetic resonance imaging: oncological and inflammatory applications

  2022cites this paper
• Lessons Learned in Practice with Li-Fraumeni Syndrome: LFS-Related Breast Cancer Treatment Strategy and Establishment of a Surveillance System

  2022cites this paper
• Li–Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment

  2022cites this paper
• Consultation d’annonce d’un syndrome de Li-Frauméni à l’enfant : enjeux psychologiques chez les différents protagonistes

  2021cites this paper
• Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Whole-body magnetic resonance imaging: technique, guidelines and key applications

  2021cites this paper
• Fortschrittliche radiologische Diagnostik bei soliden Tumoren im Kindes- und Jugendalter

  2021cites this paper
• Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy

  2021cites this paper
• Screening of cancer predisposition syndromes

  2021cites this paper
• Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening.

  2021cites this paper
• Characteristics of Li‐Fraumeni syndrome in Japan: A review study by the special committee of JSHT

  2021cites this paper
• Lung Cancer in Li-Fraumeni Syndrome

  2021cites this paper
• The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1

  2021cites this paper
• Inherited Predisposition to Gastric Cancer.

  2021cites this paper
• Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome

  2021cites this paper
• The Role of Whole‐Body MRI in Pediatric Musculoskeletal Oncology: Current Concepts and Clinical Applications

  2021cites this paper
• Bildgebung bei Tumorprädispositionssyndromen

  2021cites this paper
• Whole-body magnetic resonance imaging (WB-MRI) for cancer screening: recommendations for use

  2021cites this paper
• Genetics of Breast and Ovary Cancers Associated with Hereditary Cancers and their Clinical Management

  2021cites this paper
• Timeliness of diagnosis and treatment: the challenge of childhood cancers

  2021cites this paper
• Identification and characterization of de novo germline TP53 mutation carriers in families with Li-Fraumeni Syndrome

  2021cites this paper
• Breast cancer characteristics and surgery among women with Li‐Fraumeni syndrome in Germany—A retrospective cohort study

  2021cites this paper
• Table 25. Screening, surveillance, and diagnostic tests for cancer

  2021cites this paper
• Table 40. Li–Fraumeni syndrome

  2021cites this paper
• Medical guidelines for Li–Fraumeni syndrome 2019, version 1.1

  2021cites this paper
• Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li–Fraumeni syndrome

  2021cites this paper
• Lung cancer is also a hereditary disease

  2021cites this paper
• References

  2021cites this paper
• Quantification of Discordant Variant Interpretations in a Large Family-Based Study of Li-Fraumeni Syndrome.

  2021cites this paper
• Case Report : Li-Fraumeni Syndrome with Central Nervous System Tumors in Two Siblings

  2021cites this paper
• The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1

  2021cites this paper
• BRCA and Beyond: Comprehensive Image-rich Review of Hereditary Breast and Gynecologic Cancer Syndromes.

  2020cites this paper
• Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53

  2020cites this paper
• Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene

  2020cites this paper
• Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes

  2020cites this paper